Pfizer Inc. (NYSE:PFE) Shares Bought by Vanguard Group Inc

Vanguard Group Inc boosted its stake in Pfizer Inc. (NYSE:PFE) by 1.5% during the 3rd quarter, according to the company in its most recent disclosure …

Pfizer logoVanguard Group Inc boosted its stake in Pfizer Inc. (NYSE:PFE) by 1.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 441,792,969 shares of the biopharmaceutical company’s stock after acquiring an additional 6,620,749 shares during the period. Pfizer accounts for approximately 0.8% of Vanguard Group Inc’s holdings, making the stock its 13th biggest holding. Vanguard Group Inc owned 7.42% of Pfizer worth $19,469,816,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. Fort L.P. purchased a new position in shares of Pfizer in the 2nd quarter worth about $121,000. Selective Wealth Management purchased a new position in shares of Pfizer in the 3rd quarter worth about $155,000. Point72 Hong Kong Ltd raised its position in shares of Pfizer by 7,195.5% in the 2nd quarter. Point72 Hong Kong Ltd now owns 4,815 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 4,749 shares during the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of Pfizer in the 3rd quarter worth about $198,000. Finally, Garrison Financial Corp purchased a new position in Pfizer in the 3rd quarter worth about $200,000. Institutional investors and hedge funds own 69.53% of the company’s stock.

Shares of PFE opened at $42.91 on Wednesday. The company has a market cap of $252.82 billion, a PE ratio of 14.30, a PEG ratio of 2.43 and a beta of 0.75. Pfizer Inc. has a 1 year low of $34.37 and a 1 year high of $46.47. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.33 and a current ratio of 1.57.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.01. The business had revenue of $13.98 billion for the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.86 EPS for the current fiscal year.

Pfizer announced that its board has authorized a share repurchase program on Friday, December 14th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

In related news, insider Rady A. Johnson sold 8,700 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $41.13, for a total transaction of $357,831.00. Following the sale, the insider now owns 59,797 shares in the company, valued at approximately $2,459,450.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Douglas M. Lankler sold 5,000 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $42.75, for a total value of $213,750.00. Following the sale, the executive vice president now owns 83,592 shares in the company, valued at approximately $3,573,558. The disclosure for this sale can be found here. Insiders have sold a total of 332,526 shares of company stock worth $14,346,539 in the last 90 days. 0.09% of the stock is currently owned by insiders.

PFE has been the subject of a number of recent research reports. Cantor Fitzgerald restated a “buy” rating and set a $53.00 price target on shares of Pfizer in a research note on Tuesday, December 11th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Thursday, January 31st. Bank of America boosted their price target on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday. ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Credit Suisse Group set a $45.00 price objective on Pfizer and gave the company a “hold” rating in a research note on Thursday, December 13th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $45.16.

ILLEGAL ACTIVITY WARNING: This piece was reported by Modern Readers and is owned by of Modern Readers. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.modernreaders.com/news/2019/04/10/vanguard-group-inc-buys-6620749-shares-of-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is a Buy-Side Analyst?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Qv Investors Has Decreased Position in Microsoft (MSFT) as Stock Rose; Jane Street Group …

… CASE AGAINST DANISH TAX AUTHORITY; 10/04/2018 – C3 IOT & MICROSOFT REPORT PARTNERSHIP TO ON AI IN ENTERPRISE; 17/04/2018 …

Pfizer Inc. (NYSE:PFE) Logo

Qv Investors Inc decreased its stake in Microsoft Corp (MSFT) by 44.44% based on its latest 2018Q4 regulatory filing with the SEC. Qv Investors Inc sold 136,040 shares as the company’s stock rose 1.03% with the market. The institutional investor held 170,079 shares of the prepackaged software company at the end of 2018Q4, valued at $17.27M, down from 306,119 at the end of the previous reported quarter. Qv Investors Inc who had been investing in Microsoft Corp for a number of months, seems to be less bullish one the $922.85 billion market cap company. The stock increased 0.84% or $1.01 during the last trading session, reaching $120.29. About 6.04 million shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 20.90% since April 10, 2018 and is uptrending. It has outperformed by 16.53% the S&P500. Some Historical MSFT News: 14/03/2018 – Monaco Joins the Enterprise Ethereum Alliance; 28/03/2018 – MICROSOFT WINS COURT CASE AGAINST DANISH TAX AUTHORITY; 10/04/2018 – C3 IOT & MICROSOFT REPORT PARTNERSHIP TO ON AI IN ENTERPRISE; 17/04/2018 – Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine; 16/03/2018 – Google, Amazon and Microsoft cloud businesses helped more than double spending on data centers last year:; 09/04/2018 – MICROSOFT BLOG: ISSUE IN AZURE PORTAL ALL RESOLVED; 16/05/2018 – Microsoft is reportedly taking on Apple’s iPad with a line of low-cost tablets; 21/03/2018 – U.S. spending bill includes bid to solve international email privacy impasse; 16/03/2018 – MSFT CITES ON-GOING AZURE EMAIL SERVICES OUTAGE SINCE MARCH 15; 26/04/2018 – MICROSOFT EXPECTS CURRENCY TO BOOST SALES BY 3% IN 4Q

Jane Street Group Llc increased its stake in Pfizer Inc (Call) (PFE) by 148.29% based on its latest 2018Q4 regulatory filing with the SEC. Jane Street Group Llc bought 404,100 shares as the company’s stock declined 4.08% while stock markets rallied. The institutional investor held 676,600 shares of the health care company at the end of 2018Q4, valued at $29.53 million, up from 272,500 at the end of the previous reported quarter. Jane Street Group Llc who had been investing in Pfizer Inc (Call) for a number of months, seems to be bullish on the $237.42 billion market cap company. The stock decreased 0.18% or $0.08 during the last trading session, reaching $42.76. About 3.75M shares traded. Pfizer Inc. (NYSE:PFE) has risen 20.88% since April 10, 2018 and is uptrending. It has outperformed by 16.51% the S&P500. Some Historical PFE News: 27/03/2018 – GSK says very confident about consumer margin goal of at least 20 pct; 12/04/2018 – PFIZER INITIATES DUCHENNE MUSCULAR DYSTROPHY STUDY; 04/04/2018 – PFIZER: FDA GRANTED PRIORITY REVIEW FOR DACOMITINIB; 24/05/2018 – DOJ: Pfizer in Five-Year Corporate Integrity Agreement With Health & Human Services; 22/05/2018 – Pfizer: Study Finds Prevnar 13 Associated With Reduced Risk of Hospitalization From Certain Pneumonia in Older Adults; 03/04/2018 – RT @CNBCnow: NEW: Pfizer in talks with P&G on the sale of its consumer business, but the companies are far apart on price, sources tell @Da…; 26/04/2018 – NY Warn Notices: 4 / 26 / 2018 – Pfizer, Inc. – North Country Region; 24/05/2018 – AUSTRALIAN COURT ORDERS ACCC APPEAL VS PFIZER BE DISMISSED; 23/05/2018 – STRATA ONCOLOGY FUNDING ROUND LED PFIZER, MERCK & CO; 29/03/2018 – Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin

Analysts await Microsoft Corporation (NASDAQ:MSFT) to report earnings on April, 25. They expect $1.00 EPS, up 5.26% or $0.05 from last year’s $0.95 per share. MSFT’s profit will be $7.67B for 30.07 P/E if the $1.00 EPS becomes a reality. After $1.10 actual EPS reported by Microsoft Corporation for the previous quarter, Wall Street now forecasts -9.09% negative EPS growth.

Since October 26, 2018, it had 0 buys, and 8 insider sales for $58.46 million activity. BROD FRANK H sold 20,000 shares worth $2.15M. On Friday, October 26 the insider Nadella Satya sold $21.70M. Another trade for 36,500 shares valued at $4.06 million was made by Hogan Kathleen T on Thursday, November 8.

Investors sentiment increased to 0.94 in Q4 2018. Its up 0.13, from 0.81 in 2018Q3. It is positive, as 55 investors sold MSFT shares while 925 reduced holdings. 168 funds opened positions while 758 raised stakes. 5.48 billion shares or 3.82% more from 5.28 billion shares in 2018Q3 were reported. Clean Yield invested 1.41% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Fundsmith Llp holds 11.90 million shares. Accredited holds 0.32% or 13,946 shares. Wendell David Associates reported 120,862 shares. Bridgeway Cap Management holds 0.36% or 263,745 shares. Fulton Breakefield Broenniman Limited Liability Co has 2.89% invested in Microsoft Corporation (NASDAQ:MSFT) for 161,013 shares. Brighton Jones Ltd Liability Corporation invested 7.61% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Veritas Asset Management Limited Liability Partnership invested 5.15% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Churchill Corp accumulated 76,088 shares. Tuttle Tactical Management invested 0.77% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Greatmark Inv Prtn invested in 5.3% or 145,672 shares. Balyasny Asset Management Limited Liability reported 0% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Boston Common Asset Mgmt Limited Company invested 3.13% in Microsoft Corporation (NASDAQ:MSFT). Moreover, Grandfield Dodd Ltd Co has 4.84% invested in Microsoft Corporation (NASDAQ:MSFT) for 402,954 shares. Quantum Mgmt reported 11,666 shares.

Qv Investors Inc, which manages about $658.45 million US Long portfolio, upped its stake in Molson Coors Brewing Co (NYSE:TAP) by 104,700 shares to 579,460 shares, valued at $32.54 million in 2018Q4, according to the filing.

More notable recent Microsoft Corporation (NASDAQ:MSFT) news were published by: Nasdaq.com which released: “Technology Sector Update for 04/08/2019: DXC, ACN, TDC, MSFT, AAPL, IBM, CSCO, GOOG – Nasdaq” on April 08, 2019, also Nasdaq.com with their article: “Technology Sector Update for 04/10/2019: SFET, IZEA, TSM, MSFT, AAPL, IBM, CSCO, GOOG – Nasdaq” published on April 10, 2019, Seekingalpha.com published: “Microsoft investigating harassment claims – Seeking Alpha” on April 04, 2019. More interesting news about Microsoft Corporation (NASDAQ:MSFT) were released by: Seekingalpha.com and their article: “Microsoft helps launch Quantum Nexus – Seeking Alpha” published on March 18, 2019 as well as Nasdaq.com‘s news article titled: “Daily Dividend Report: IIPR, MSFT, AXP, ADT, CASY – Nasdaq” with publication date: March 12, 2019.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: 247Wallst.com which released: “The 5 Most Shorted Dow Stocks – 24/7 Wall St.” on April 10, 2019, also Seekingalpha.com with their article: “Pfizer Steps Further In The Door For Gene Therapies – Seeking Alpha” published on March 22, 2019, Investorplace.com published: “The Case Against Pfizer Stock and the Rest of the Industry – Investorplace.com” on March 15, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: Solid, Stable Returns – Seeking Alpha” published on April 10, 2019 as well as 247Wallst.com‘s news article titled: “Why Pfizer Is Getting Deeper Into Gene Therapy – 24/7 Wall St.” with publication date: March 20, 2019.

Jane Street Group Llc, which manages about $47.50B US Long portfolio, decreased its stake in Ishares Tr (HEWG) by 89,711 shares to 58,236 shares, valued at $1.38M in 2018Q4, according to the filing. It also reduced its holding in Tahoe Res Inc (NYSE:TAHO) by 247,798 shares in the quarter, leaving it with 161,202 shares, and cut its stake in Analog Devices Inc (NASDAQ:ADI).

Investors sentiment decreased to 0.74 in 2018 Q4. Its down 0.11, from 0.85 in 2018Q3. It dropped, as 42 investors sold PFE shares while 792 reduced holdings. 141 funds opened positions while 477 raised stakes. 4.05 billion shares or 2.27% more from 3.96 billion shares in 2018Q3 were reported. Winfield Associates Incorporated holds 0.48% or 18,072 shares in its portfolio. Advisors Cap Management Ltd reported 52,143 shares stake. D Scott Neal holds 10,823 shares or 0.26% of its portfolio. Chesley Taft Assoc Limited stated it has 0.91% of its portfolio in Pfizer Inc. (NYSE:PFE). The Massachusetts-based Arrowstreet Cap Partnership has invested 0.01% in Pfizer Inc. (NYSE:PFE). Salem Capital Mgmt Inc holds 169,298 shares. Tci Wealth Advisors Inc invested in 1.47% or 69,322 shares. Wellington Management Gru Ltd Liability Partnership holds 0.83% or 75.60 million shares in its portfolio. Farmers Communication owns 1.5% invested in Pfizer Inc. (NYSE:PFE) for 109,808 shares. Korea Inv Corporation has invested 1.01% in Pfizer Inc. (NYSE:PFE). Brookstone Cap Management owns 80,278 shares. Horan Cap Advisors Limited Liability Com holds 0.22% or 7,677 shares. Illinois-based Trust Department Mb Finance Bank & Trust N A has invested 0.15% in Pfizer Inc. (NYSE:PFE). Wealth Architects Ltd Liability Corporation has invested 0.15% in Pfizer Inc. (NYSE:PFE). Bb&T Securities Ltd Liability Corp holds 0.96% in Pfizer Inc. (NYSE:PFE) or 2.00M shares.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Pfizer, Concerto collaborate on AI in precision oncology

AI work to date in the health sphere has focused mainly on uses in imaging and diagnostics, according to consultants at CB Insights, but clinical …

Dive Brief:

  • Precision oncology-focused Concerto HealthAI said Tuesday it will work with Pfizer to apply real-world datasets and artificial intelligence techniques to develop new and more precise treatment options for patients with solid tumors and hematologic malignancies.
  • The collaboration aims to speed the pace of actionable patient insights for Pfizer’s investigational therapies as well as commercially available therapeutics, Concerto said.
  • It is Concerto’s second AI collaboration with a big pharma company in recent weeks. The company in late March announced an agreement with Bristol-Myers Squibb to use real-world evidence to accelerate clinical trials and improve precision treatment for a range of cancers.

Dive Insight:

AI work to date in the health sphere has focused mainly on uses in imaging and diagnostics, according to consultants at CB Insights, but clinical insights and risk analytics, clinical trials and drug discovery have also attracted a lot of funding.

Concerto’s work with Pfizer is expected to focus on identifying new and more precise treatment options, refining study designs and speeding completion times for outcomes studies. The effort aims to find and help patients who may benefit from new therapeutic combinations.

The agreement will use Concerto HealthAI’s eurekaHealthplatform, AI models and real-world clinical electronic medical record and healthcare claims, Concerto said. Data from clinical practices participating in the American Society of Clinical Oncology’s CancerLinQ initiative and others will be used.

The collaboration will develop new synthetic control arm and prospective study designs, for both pre- and post-approval research, based on real-world data outcomes for therapeutics, Concerto said. The plan is to build on work in study designs based on real-world data that CancerLinQ, Concerto HealthAI and others have undertaken in collaboration with FDA.

A Concerto HealthAI-Pfizer joint steering committee will oversee the collaboration, with the first outcomes research and publications expected in early 2020.

Pfizer is among the healthcare companies investing heavily in AI and also recently teamed with IBM Watson to identify better targets for cancer during the discovery phase, though Watson’s abilities have come into question.

Related Posts:

  • No Related Posts

Hexavest INC Has Cut Its Pfizer INC El (PFE) Holding by $21.00 Million

Benchmark Capital holds 3.64% of its portfolio in Pfizer Inc. (NYSE:PFE) for 83,925 shares. 33,421 are owned by Peak Asset Ltd. Cadence Mgmt Lc …

Pfizer Inc. (NYSE:PFE) LogoInvestors sentiment decreased to 0.74 in 2018 Q4. Its down 0.11, from 0.85 in 2018Q3. It is negative, as 42 investors sold PFE shares while 792 reduced holdings. 141 funds opened positions while 477 raised stakes. 4.05 billion shares or 2.27% more from 3.96 billion shares in 2018Q3 were reported. Kcm Investment Advisors Ltd Com invested in 157,590 shares or 0.45% of the stock. Godshalk Welsh Capital Incorporated has invested 1.26% of its portfolio in Pfizer Inc. (NYSE:PFE). Bokf Na holds 804,453 shares or 1% of its portfolio. River & Mercantile Asset Mngmt Limited Liability Partnership holds 268,452 shares. Davidson Inv Advsr stated it has 2.76% in Pfizer Inc. (NYSE:PFE). Benchmark Capital holds 3.64% of its portfolio in Pfizer Inc. (NYSE:PFE) for 83,925 shares. 33,421 are owned by Peak Asset Ltd. Cadence Mgmt Lc owns 146,525 shares or 0.65% of their US portfolio. Savant Capital Limited Liability Co has invested 0.53% in Pfizer Inc. (NYSE:PFE). Nomura accumulated 529,323 shares. Crossvault Capital Mgmt Ltd Liability invested in 58,894 shares or 1.46% of the stock. Sterling Strategies Ltd Liability Com holds 0% or 4,363 shares in its portfolio. Hwg Ltd Partnership owns 40,482 shares. 192,312 were accumulated by First Amer Fincl Bank. Meridian Management Com holds 30,964 shares.

Since January 30, 2019, it had 0 buys, and 1 sale for $1.81 million activity.

Hexavest Inc decreased its stake in Pfizer Inc El (PFE) by 8.91% based on its latest 2018Q4 regulatory filing with the SEC. Hexavest Inc sold 488,288 shares as the company’s stock declined 4.08% while stock markets rallied. The hedge fund held 4.99M shares of the health care company at the end of 2018Q4, valued at $217.92 million, down from 5.48 million at the end of the previous reported quarter. Hexavest Inc who had been investing in Pfizer Inc El for a number of months, seems to be less bullish one the $239.51 billion market cap company. The stock increased 0.35% or $0.15 during the last trading session, reaching $43.14. About 14.52M shares traded. Pfizer Inc. (NYSE:PFE) has risen 20.88% since April 9, 2018 and is uptrending. It has outperformed by 16.51% the S&P500.

Hexavest Inc, which manages about $16.29 billion and $6.88 billion US Long portfolio, upped its stake in Tjx Companies Inc Co L (NYSE:TJX) by 611,412 shares to 1.32M shares, valued at $58.97M in 2018Q4, according to the filing. It also increased its holding in Aes Corp (NYSE:AES) by 2.13M shares in the quarter, for a total of 4.64M shares, and has risen its stake in Wheaton Precious Metco L.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on May, 7. They expect $0.77 earnings per share, 0.00 % or $0.00 from last year’s $0.77 per share. PFE’s profit will be $4.27 billion for 14.01 P/E if the $0.77 EPS becomes a reality. After $0.64 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts 20.31 % EPS growth.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “FDA OKs Pfizer’s Herceptin biosimilar – Seeking Alpha” on March 12, 2019, also 247Wallst.com with their article: “Pfizer Moves Over Half a Billion for Wilson Disease Treatment – 24/7 Wall St.” published on March 20, 2019, Investorplace.com published: “The Case Against Pfizer Stock and the Rest of the Industry – Investorplace.com” on March 15, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Streetinsider.com and their article: “Pfizer (PFE) PT Raised to $48 at BofA/Merrill Lynch Ahead of Orphan Drug Catalyst – StreetInsider.com” published on April 01, 2019 as well as Benzinga.com‘s news article titled: “Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts (NYSE:PFE) – Benzinga” with publication date: April 01, 2019.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 7 analysts covering Pfizer (NYSE:PFE), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Pfizer had 12 analyst reports since October 31, 2018 according to SRatingsIntel. The firm earned “Outperform” rating on Thursday, January 31 by Argus Research. Credit Suisse upgraded the stock to “Outperform” rating in Thursday, January 31 report. Credit Suisse maintained the shares of PFE in report on Wednesday, October 31 with “Neutral” rating. The firm has “Buy” rating given on Tuesday, February 19 by Cantor Fitzgerald. The firm earned “Market Perform” rating on Thursday, November 1 by BMO Capital Markets. Citigroup maintained the stock with “Sell” rating in Tuesday, November 6 report. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Bank of America on Monday, April 1. The stock of Pfizer Inc. (NYSE:PFE) earned “Neutral” rating by UBS on Wednesday, January 23. The firm earned “Neutral” rating on Tuesday, December 11 by JP Morgan. The firm has “Hold” rating given on Monday, February 25 by UBS.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Pfizer (PFE) Holder Asset Management Group Increased Stake by $313298 as Market Value …

Artemis Investment Management Llp decreased its stake in Intel Corp … 17/05/2018 – Intel Corporation’s (INTC) CEO Brian Krzanich Hosts 2018 …

Pfizer Inc. (NYSE:PFE) Logo

Asset Management Group Inc increased its stake in Pfizer Inc (PFE) by 19.67% based on its latest 2018Q4 regulatory filing with the SEC. Asset Management Group Inc bought 7,286 shares as the company’s stock declined 4.08% while stock markets rallied. The institutional investor held 44,328 shares of the health care company at the end of 2018Q4, valued at $1.94 million, up from 37,042 at the end of the previous reported quarter. Asset Management Group Inc who had been investing in Pfizer Inc for a number of months, seems to be bullish on the $239.45 billion market cap company. The stock increased 0.33% or $0.14 during the last trading session, reaching $43.13. About 10.74 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 20.88% since April 8, 2018 and is uptrending. It has outperformed by 16.51% the S&P500. Some Historical PFE News: 23/03/2018 – PFIZER SAYS CONTINUES TO EVALUATE POTENTIAL STRATEGIC ALTERNATIVES FOR THE CONSUMER HEALTHCARE BUSINESS, INCLUDING A SPIN-OFF,SALE OR OTHER TRANSACTION, AND PFIZER ULTIMATELY RETAINING THE BUSINESS; 03/04/2018 – PFIZER INC PFE.N SAYS AGREEMENT AIMS TO ACCELERATE THE DEVELOPMENT OF PFIZER’S CAR T CELL THERAPY; 17/04/2018 – MERCK – FIRST STUDY TO EVALUATE PCV-15 FOLLOWED BY PNEUMOCOCCAL VACCINE POLYVALENT ONE YEAR LATER IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER; 23/03/2018 – PFIZER INC – ADVERSE EVENT PROFILE OF CHANTIX/CHAMPIX OBSERVED IN STUDY OF ADOLESCENT SMOKERS WAS SIMILAR TO THAT SEEN IN STUDIES OF ADULTS; 18/05/2018 – Johnson & Johnson scraps Alzheimer’s trials on safety concerns; 05/03/2018 – Dan R. Littman Elected to Pfizer’s Bd of Directors; 17/04/2018 – HEALTH CANADA SAYS WORKING WITH PFIZER INC AND U.S. FDA TO ADDRESS CANADIAN SHORTAGE OF MYLAN’S EPIPEN ALLERGY ANTIDOTE; 24/05/2018 – The settlement announced by the U.S. Department of Justice resolves allegations that Pfizer violated the federal False Claims Act between 2012 and 2016; 25/05/2018 – IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase lll Pacific Trial for Unresectable Stage lll Non-Small Cell Lung Cancer; 01/05/2018 – Pfizer Says It Doesn’t Need a Major Deal; Investors Unconvinced

Artemis Investment Management Llp decreased its stake in Intel Corp (INTC) by 18.15% based on its latest 2018Q4 regulatory filing with the SEC. Artemis Investment Management Llp sold 116,364 shares as the company’s stock rose 10.40% with the market. The institutional investor held 524,671 shares of the semiconductors company at the end of 2018Q4, valued at $24.64M, down from 641,035 at the end of the previous reported quarter. Artemis Investment Management Llp who had been investing in Intel Corp for a number of months, seems to be less bullish one the $250.49 billion market cap company. The stock increased 0.14% or $0.08 during the last trading session, reaching $55.68. About 11.03M shares traded. Intel Corporation (NASDAQ:INTC) has risen 12.75% since April 8, 2018 and is uptrending. It has outperformed by 8.38% the S&P500. Some Historical INTC News: 22/05/2018 – Al Retail Leader Rubikloud Collaborates with Intel to Revitalize the Shopping Experience; 26/04/2018 – Intel earnings: 87 cents per share, vs 72 cents expected; 02/05/2018 – MERKEL: NEW ISRAELI INTEL. ON IRAN MUST BE REVIEWED BY IAEA; 15/05/2018 – l-COM 2018: Ekimetrics won the Intel challenge hackathon final showcasing its consultants’ excellence in Data Science; 17/05/2018 – Intel Corporation’s (INTC) CEO Brian Krzanich Hosts 2018 Stockholders’ Meeting (Transcript); 12/03/2018 – Broadcom Gives Notice, and Street Debates Potential Intel Take-Out — Barron’s Blog; 06/04/2018 – The Daily Beast: @attackerman Although the Nat Intel Director said a “decision” was reached, sources say the course of the; 15/03/2018 – Mark R. Warner: Joint Statement: Senate Intel Committee Leaders on Russian Nerve Agent Attack on British Soil; 15/05/2018 – Intel wants to expand its production operations in Israel, with the government saying the U.S. chipmaker would invest about $5 billion; 09/03/2018 – Oregonian: Qualcomm + Broadcom = Intel? Sounds far-fetched

Analysts await Intel Corporation (NASDAQ:INTC) to report earnings on April, 25. They expect $0.87 EPS, 0.00% or $0.00 from last year’s $0.87 per share. INTC’s profit will be $3.91B for 16.00 P/E if the $0.87 EPS becomes a reality. After $1.28 actual EPS reported by Intel Corporation for the previous quarter, Wall Street now forecasts -32.03% negative EPS growth.

Since October 25, 2018, it had 2 buys, and 9 sales for $893,356 activity. 8,552 shares were sold by Shenoy Navin, worth $409,874. Shares for $245,993 were bought by SWAN ROBERT HOLMES. 2,235 Intel Corporation (NASDAQ:INTC) shares with value of $102,050 were sold by Rodgers Steven Ralph.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Nasdaq.com which released: “What’s Next for AMD, Intel (INTC), Nvidia (NVDA) & Micron (MU) Stock? – Nasdaq” on April 03, 2019, also Seekingalpha.com with their article: “Should Intel Worry About AMD? – Seeking Alpha” published on March 22, 2019, Seekingalpha.com published: “In Case Intel’s Share Price Collapses – Seeking Alpha” on April 07, 2019. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Nasdaq.com and their article: “Nvidia Joins Bidding for Israeli Chipmaker Mellanox: Report – Nasdaq” published on March 10, 2019 as well as Bizjournals.com‘s news article titled: “Intel confirms layoffs, stays mum on details – Portland Business Journal” with publication date: March 29, 2019.

Investors sentiment increased to 1 in 2018 Q4. Its up 0.15, from 0.85 in 2018Q3. It improved, as 52 investors sold INTC shares while 677 reduced holdings. 141 funds opened positions while 588 raised stakes. 2.96 billion shares or 3.57% more from 2.86 billion shares in 2018Q3 were reported. Wolverine Asset Ltd Liability accumulated 387 shares. First Commercial Bank Of Mount Dora Invest Services holds 95,408 shares or 2.23% of its portfolio. Letko Brosseau Assoc has 2.13M shares. Ballentine Ptnrs Limited Liability owns 30,489 shares for 0.08% of their portfolio. First Interstate Bancshares owns 0.35% invested in Intel Corporation (NASDAQ:INTC) for 30,580 shares. Da Davidson invested in 0.83% or 908,399 shares. Cap Int Ca has invested 0.29% of its portfolio in Intel Corporation (NASDAQ:INTC). Gillespie Robinson Grimm stated it has 5,230 shares. Putnam Fl Inv holds 0.78% or 152,240 shares. Mackenzie Fin owns 2.25 million shares. Meristem Family Wealth Ltd Liability Com reported 4,800 shares stake. Cap City Com Fl accumulated 13,573 shares. Golub Grp Ltd Liability Corp owns 0.18% invested in Intel Corporation (NASDAQ:INTC) for 39,618 shares. 306,783 are owned by Guardian Tru. Clark Estates Inc reported 0.16% in Intel Corporation (NASDAQ:INTC).

Artemis Investment Management Llp, which manages about $7.66 billion US Long portfolio, upped its stake in Bank N S Halifax (NYSE:BNS) by 61,700 shares to 212,200 shares, valued at $10.56M in 2018Q4, according to the filing. It also increased its holding in Las Vegas Sands Corp (NYSE:LVS) by 526,123 shares in the quarter, for a total of 833,738 shares, and has risen its stake in Abbott Labs (NYSE:ABT).

Since January 30, 2019, it had 0 buys, and 1 insider sale for $1.81 million activity.

Asset Management Group Inc, which manages about $284.95 million and $243.51M US Long portfolio, decreased its stake in Vanguard Corp Bond Etf Short (VCSH) by 24,312 shares to 22,142 shares, valued at $1.73 million in 2018Q4, according to the filing. It also reduced its holding in Vanguard Bond Index Fund Intermediate Te (BIV) by 7,430 shares in the quarter, leaving it with 16,664 shares, and cut its stake in Invesco Ny Muni Amt Free Mun Bd Etf (PZT).

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Investorplace.com which released: “The Case Against Pfizer Stock and the Rest of the Industry – Investorplace.com” on March 15, 2019, also Seekingalpha.com with their article: “Pfizer Steps Further In The Door For Gene Therapies – Seeking Alpha” published on March 22, 2019, 247Wallst.com published: “Pfizer and Apple Remain Most Shorted Dow Stocks – 24/7 Wall St.” on March 27, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “FDA OKs Pfizer’s Herceptin biosimilar – Seeking Alpha” published on March 12, 2019 as well as Streetinsider.com‘s news article titled: “Pfizer (PFE) Announces VIZIMPRO Receives MAA in EU for First-Line Treatment of Adult Patients with EGFR-Mutated NSCLC – StreetInsider.com” with publication date: April 03, 2019.

Investors sentiment decreased to 0.74 in Q4 2018. Its down 0.11, from 0.85 in 2018Q3. It turned negative, as 42 investors sold PFE shares while 792 reduced holdings. 141 funds opened positions while 477 raised stakes. 4.05 billion shares or 2.27% more from 3.96 billion shares in 2018Q3 were reported. Hrt Fin Lc stated it has 1.22% in Pfizer Inc. (NYSE:PFE). Conning Inc holds 1.67% or 1.12M shares. Matarin Cap Mngmt Limited Liability Corporation has invested 0% in Pfizer Inc. (NYSE:PFE). Cidel Asset, Ontario – Canada-based fund reported 9,978 shares. Pictet Asset Mngmt Ltd reported 3.92 million shares. 19,249 are owned by Northstar Inv Ltd. Lombard Odier Asset Mngmt (Switzerland) Sa owns 579,173 shares for 2.87% of their portfolio. Sumitomo Mitsui Asset Management Communication Ltd accumulated 542,925 shares. Continental Advsr Ltd has invested 2.35% of its portfolio in Pfizer Inc. (NYSE:PFE). Westchester Cap invested in 190,160 shares. First City Cap Management stated it has 2.22% of its portfolio in Pfizer Inc. (NYSE:PFE). Serv has invested 0.94% in Pfizer Inc. (NYSE:PFE). Mycio Wealth Prns Lc invested 0.19% in Pfizer Inc. (NYSE:PFE). Inr Advisory Service Limited Liability invested in 79 shares. Aviva Plc invested in 1.21% or 3.71M shares.

Intel Corporation (NASDAQ:INTC) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts